News stories about Teligent (NASDAQ:TLGT) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Teligent earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.9278869990966 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several research firms have recently issued reports on TLGT. Zacks Investment Research raised shares of Teligent from a “sell” rating to a “hold” rating in a research report on Tuesday. Canaccord Genuity decreased their price objective on shares of Teligent from $4.00 to $3.50 and set a “hold” rating for the company in a research report on Friday, March 2nd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. Teligent has an average rating of “Hold” and an average price target of $6.83.
Teligent (NASDAQ:TLGT) traded up $0.06 during trading on Wednesday, hitting $2.63. 892,404 shares of the stock traded hands, compared to its average volume of 497,523. The stock has a market cap of $139.37, a PE ratio of -11.95 and a beta of 1.13. Teligent has a 1-year low of $2.51 and a 1-year high of $9.54. The company has a current ratio of 3.28, a quick ratio of 2.71 and a debt-to-equity ratio of 2.23.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.